Merck shares rose after partner Kelun-Biotech reported positive late-stage trial results for a Keytruda combination treatment ...

Merck & Co. Inc. (NYSE:MRK) is one of the best low risk stocks to buy in 2026. On May 18, Merck announced that its pivotal ...

Merck (MRK) shares rose nearly 5% in early trade on Friday after the company said a European medicines committee issued a ...

Merck (MRK) stock gains as a cancer drug the company develops with Kelun-Biotech bests its Keytruda blockbuster in a ...

The trial assesses Precem-TcT efficacy and safety alone or with bevacizumab in mCRC patients after previous therapies.

Merck stock popped early Friday after European officials recommended approving its combination for a form of bladder cancer.

Summit Therapeutics (SMMT) stock faced a downgrade at H.C. Wainwright after late-stage trial data for Merck’s (MRK) lung cancer drug sac-TMT. Read more here.

Biotech’s antibody-drug conjugate significantly improved progression-free and overall survival in a pivotal endometrial ...

By Siddhi Mahatole May 21 (Reuters) - Sichuan Kelun-Biotech Biopharmaceutical said on Thursday its experimental treatment ...

Moderna and Merck's combination therapy for skin cancer helped reduce risk of cancer spreading to another part of the body ...

A type of targeted chemotherapy developed by China-based Kelun-Biotech and licensed to Merck cut the risk of tumor ...

Treatment with the TROP2 ADC sac-TMT led to a 70% objective response rate and progression-free survival was “significantly ...